Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 8/20 | 0.64 |
| ▸ | TLR2 | O60603 | 8/20 | 0.64 |
| ▸ | FBP1 | P09467 | 6/20 | 0.63 |
| ▸ | VCP | P55072 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | TERT | O14746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235501 | 0.85 | FBP1 (0.68) | TLR4TLR2FBP1VCPEGFR | |
| SCHEMBL3235505 | 0.85 | FBP1 (0.68) | TLR4TLR2FBP1VCPEGFR | |
| SCHEMBL6041116 | 0.83 | EGFR (0.69) | TLR4TLR2FBP1VCPEGFR | |
| SCHEMBL31287227 | 0.78 | FBP1 (1.00) | TLR4TLR2FBP1VCPMAOA | |
| SCHEMBL8765211 | 0.78 | FBP1 (1.00) | TLR4TLR2FBP1VCPMAOA | |
| SCHEMBL278627 | 0.78 | FBP1 (1.00) | TLR4TLR2FBP1VCPMAOA | |
| SCHEMBL1244858 | 0.78 | ACHE (0.58) | MAOAMAOB | |
| SCHEMBL792987 | 0.78 | FBP1 (1.00) | TLR4TLR2FBP1VCPMAOA | |
| SCHEMBL510207 | 0.78 | TLR4 (1.00) | TLR4TLR2FBP1MAOAMAOB | |
| SCHEMBL28432983 | 0.78 | ACHE (0.51) | TLR4TLR2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| EP-1307447-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | TLR4 3117/4885TLR2 3148/4885FBP1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.